Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
Baxter
Colorcon
Merck
Covington

Generated: September 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,629,924

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,629,924
Title:Conjugates of CC-1065 analogs and bifunctional linkers
Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
Inventor(s): Beusker; Patrick Henry (Nijmegen, NL), Coumans; Rudy Gerardus Elisabeth (Nijmegen, NL), Elgersma; Ronald Christiaan (Nijmegen, NL), Menge; Wiro Michael Petrus Bernardus (Nijmegen, NL), Joosten; Johannes Albertus Frederikus (Nijmegen, NL), Spijker; Henri Johannes (Nijmegen, NL), De Groot; Franciscus Marinus Hendrikus (Nijmegen, NL)
Assignee: Syntarga BV (Nijmegen, NL)
Application Number:13/642,847
Patent Claims:1. A compound having the formula ##STR00636## wherein R is (CH.sub.2CH.sub.2O).sub.2H, (CH.sub.2).sub.3C(O)NH.sub.2, (CH.sub.2).sub.4C(NH.sub.2)COOH, (CH.sub.2).sub.3COOH, (CH.sub.2).sub.3NHC(O)NH.sub.2, or (CH.sub.2CH.sub.2O).sub.3H; q ranges from 1 to 4; and Ab is selected from trastuzumab or an epitope-binding functional fragment of trastuzumab.

2. The compound according to claim 1, wherein R is (CH.sub.2CH.sub.2O).sub.2H.

3. The compound according to claim 2, wherein Ab is trastuzumab.

4. The compound according to claim 1, wherein q is approximately 2.

5. A composition comprising a mixture of at least two compounds according to claim 1, wherein said at least two compounds have the same R substituents but different values for q.

6. The composition according to claim 5, wherein Ab in said at least two compounds is trastuzumab.

7. The composition according to claim 6, wherein the mixture of compounds has an average q value of approximately 2.

8. The composition according to claim 7, wherein R is (CH.sub.2CH.sub.2O).sub.2H.

9. A pharmaceutical composition, comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition, comprising a compound according to claim 3 and a pharmaceutically acceptable carrier.

11. The compound according to claim 1, wherein R is (CH.sub.2).sub.4C(NH.sub.2)COOH.

Summary for Patent:   Try a Free Trial

PCT Information
PCT FiledApril 21, 2011PCT Application Number:PCT/NL2011/050278
PCT Publication Date:October 27, 2011PCT Publication Number:WO2011/133039

Details for Patent 9,629,924

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Syntarga BV (Nijmegen, NL) 2037-05-25 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Chubb
Federal Trade Commission
US Department of Justice
Citi
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.